Now available HERNEXEOS®

HERNEXEOS® (zongertinib tablets), for oral use, is indicated for treating adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC). This treatment is for patients whose tumors have specific HER2 (ERBB2) tyrosine kinase domain activating mutations, identified by an FDA-approved test, and who have previously received systemic therapy.

Please see full prescribing information here.